The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to attract notable expansion opportunities in the upcoming years. This growth can be attributed to many factors including increasing occurrence of the antibiotic resistant strains development among population of all age groups.
Staphylococcus aureus refers to bacteria generally seen on the skin or nose of healthy individuals. Methicillin-resistant staphylococcus aureus (MRSA) can be defined as a staphylococcus aureus type, which shows resistance to beta-lactam antibiotic named methicillin.
Some of the prominent players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma. Presence of several prominent companies makes the competitive landscape of the market highly intense, which encourages enterprises to use organic as well as inorganic strategies in order to stay ahead in the competition.
Leading organizations in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are investing heavily in the clinical trials and R&D projects, which are concentrated on the formulation of exclusive drug molecules. Moreover, many players are focusing on the launch of generic drugs against the presently available products that have lost the patent exclusivity.
The COVID-19 pandemic has shown impact major industries including the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. Companies have developed several policies and strategies in order to address this issue and ensure consistent revenue generation.
Several companies from the North America region, specifically the U.S., are increasing investments toward the R&D projects, which are focused on the development of screening tools for MRSA infection. This factor has helped in making North America as leading market region in the methicillin-resistant staphylococcus aureus (MRSA) drugs market. Moreover, Asia Pacific is expected to emerge as fastest growing region for the market in the years to come.
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market: Snapshot
Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact. Global MRSA drugs market accounted for a revenue of US$ 2,967.0 Mn in 2016, and is estimated to reach the value of US$ 3,908.2 Mn by the end of 2025, reflecting a CAGR of 3.2% during the forecast period.
According to CDC, two in every 100 people carry MRSA. Prolonged stay of patients in long-term health care facilities is a major factor giving rise to a serious issue of surplus MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a family of health care databases in the U.S., the rate of deaths of hospitalized patients caused by MRSA infections is higher than non-hospitalized patients (4.7% vs. 2.1% respectively). Improved screening of antibiotic resistant strains of bacteria by using technologically advanced diagnostic tools, and upsurge in the consumption of antibiotics across the globe are the major factors expected to fuel the growth of global MRSA drugs market during the forecast period. Key companies are entering the distribution agreements with the emerging regional players to improve the accessibility of their anti-MRSA agents. Basilea Pharmaceutica, one of the leading MRSA drugs manufacturer, entered into a license agreement for its anti-MRSA antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (China). Such key strategies being adopted by the manufacturers is expected to propel the growth of MRSA drugs market during the forecast period. There is significant unmet need for the MRSA infection, which create huge opportunities for existing players and new entrants in the market. Also adopting the strategies such as establishing commercial partnerships for co-development and commercialization of anti-MRSA agents provide scope for opportunities in the global MRSA drugs market. However, lack of systematic surveillance for MRSA infection in developing countries is likely to hamper the growth of MRSA drugs market during 2017-2025.
The global MRSA drugs market is segmented on the basis of drug class, route of administration, and distribution channel. On the basis of drug class, the global MRSA drugs market is classified as lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonists, and others. Lipopeptide drug class held the maximum market share in 2016 in terms of revenue, owing to the established market for lipopeptides such as Daptomycin owing to efficient distribution by manufacturers and distributors across the globe. Tetracycline and Lipoglycopeptide are likely to register moderate CAGR by 2025. However, others drug class segment, which is comprised of fluoroquinolones, streptogramins, etc., is anticipated to witness significant CAGR during the forecast period, which is attributable to the rising prevalence of MRSA infection in community settings of the developing countries. Based on the route of administration, the global MRSA market is segmented into oral and parenteral. Parenteral segment accounted for highest revenue in 2016, and is expected to continue to lead the market during 2017-2025. The estimated dominance of the segment is attributed to its preference as a first line of therapy in the MRSA treatment. In terms of distribution channel, the global MRSA drugs market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Rising number of multispecialty hospitals worldwide, and improved supply of the generic MRSA drugs in the hospital pharmacies across the globe are the major factors for the dominance of hospital pharmacy segment in terms of revenue in 2016. However, online pharmacy is expected to grow at relatively significant CAGR during 2017-2025, due to availability of antibiotics on the online platform with attractive offers and discounts.
Geographically, global MRSA drugs market is divided into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for maximum revenue in 2016, owing to the strategic presence of key antibiotic manufacturing companies in the U.S. North America is estimated to remain dominant throughout the forecast period, which is attributable to the increasing investment by key players in the R&D of novel drug molecules against MRSA infection. However, rising awareness about the antibiotic resistant bacterial infections in the emerging economies of Asian countries, and rising incidence of hospital-acquired MRSA infection in India & China are the major factors for the estimated growth of Asia Pacific with relatively significant CAGR by 2025.
The prominent players operating in the global MRSA Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the R&D and clinical trials of unique drug molecules, and introducing the generic drugs against the existing products which have lost the patent exclusivity are the major strategies being adopted by key manufacturers to stay ahead in the rising competition.
The Global MRSA drugs Market has been segmented as given below:
| Attribute | Detail |
|---|---|
|
Drug Class |
|
|
Administration |
|
|
Distribution Channel |
|
|
Region |
|
Methicillin-resistant staphylococcus aureus (MRSA) drugs market to reach over US$ 3.9 Bn by 2025
Methicillin-resistant staphylococcus aureus (MRSA) drugs market is projected to register CAGR of over 3.2% from 2017 to 2025
Methicillin-resistant staphylococcus aureus (MRSA) drugs market is driven by rising incidence of the development of antibiotic resistant strains among all age groups
Asia Pacific accounted for a major share of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market
Key players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market
4. Market Overview
4.1. Drug Class Overview
4.2. Global MRSA Drugs Market Outlook
5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)
7. MRSA Drugs: Pipeline Analysis
8. MRSA Drugs Market: Competitive Landscape of Key Players
9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Drug Class, 2015-2025
9.3.1. Lipopeptide
9.3.2. Oxazolidinone
9.3.3. Cephalosporin
9.3.4. Tetracycline
9.3.5. Lipoglycopeptide
9.3.6. Folate Antagonist
9.3.7. Others
9.4. Market Attractiveness By Drug Class
9.5. Key Trends
10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Route of Administration, 2015-2025
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Attractiveness By Route of Administration
10.5. Key Trends
11. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Distribution Channel, 2015-2025
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Market Attractiveness By Distribution Channel
11.5. Key Trends
12. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Country/Region
13. North America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2015-2025
13.2.1. Lipopeptide
13.2.2. Oxazolidinone
13.2.3. Cephalosporin
13.2.4. Tetracycline
13.2.5. Lipoglycopeptide
13.2.6. Folate Antagonist
13.2.7. Others
13.3. Market Value Forecast By Route of Administration, 2015-2025
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast By Distribution Channel, 2015-2025
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Market Value Forecast By Country, 2015-2025
13.5.1. U.S.
13.5.2. Canada
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country
14. Europe Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2015-2025
14.2.1. Lipopeptide
14.2.2. Oxazolidinone
14.2.3. Cephalosporin
14.2.4. Tetracycline
14.2.5. Lipoglycopeptide
14.2.6. Folate Antagonist
14.2.7. Others
14.3. Market Value Forecast By Route of Administration, 2015-2025
14.3.1. Oral
14.3.2. Parenteral
14.4. Market Value Forecast By Distribution Channel, 2015-2025
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. Market Value Forecast By Country, 2015-2025
14.5.1. Germany
14.5.2. U.K.
14.5.3. France
14.5.4. Spain
14.5.5. Italy
14.5.6. Russia
14.5.7. Rest of Europe
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country
15. Asia Pacific Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Class, 2015-2025
15.2.1. Lipopeptide
15.2.2. Oxazolidinone
15.2.3. Cephalosporin
15.2.4. Tetracycline
15.2.5. Lipoglycopeptide
15.2.6. Folate Antagonist
15.2.7. Others
15.3. Market Value Forecast By Route of Administration, 2015-2025
15.3.1. Oral
15.3.2. Parenteral
15.4. Market Value Forecast By Distribution Channel, 2015-2025
15.4.1. Hospital Pharmacy
15.4.2. Retail Pharmacy
15.4.3. Online Pharmacy
15.5. Market Value Forecast By Country, 2015-2025
15.5.1. China
15.5.2. Japan
15.5.3. India
15.5.4. Australia & New Zealand
15.5.5. Rest of Asia Pacific
15.6. Market Attractiveness Analysis
15.6.1. By Drug Class
15.6.2. By Route of Administration
15.6.3. By Distribution Channel
15.6.4. By Country
16. Latin America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
16.1. 16.1.Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Drug Class, 2015-2025
16.2.1. Lipopeptide
16.2.2. Oxazolidinone
16.2.3. Cephalosporin
16.2.4. Tetracycline
16.2.5. Lipoglycopeptide
16.2.6. Folate Antagonist
16.2.7. Others
16.3. Market Value Forecast By Route of Administration, 2015-2025
16.3.1. Oral
16.3.2. Parenteral
16.4. Market Value Forecast By Distribution Channel, 2015-2025
16.4.1. Hospital Pharmacy
16.4.2. Retail Pharmacy
16.4.3. Online Pharmacy
16.5. Market Value Forecast By Country, 2015-2025
16.5.1. Brazil
16.5.2. Mexico
16.5.3. Rest of Latin America
16.6. Market Attractiveness Analysis
16.6.1. By Drug Class
16.6.2. By Route of Administration
16.6.3. By Distribution Channel
16.6.4. By Country
17. Middle East & Africa Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast By Drug Class, 2015-2025
17.2.1. Lipopeptide
17.2.2. Oxazolidinone
17.2.3. Cephalosporin
17.2.4. Tetracycline
17.2.5. Lipoglycopeptide
17.2.6. Folate Antagonist
17.2.7. Others
17.3. Market Value Forecast By Route of Administration, 2015-2025
17.3.1. Oral
17.3.2. Parenteral
17.4. Market Value Forecast By Distribution Channel, 2015-2025
17.4.1. Hospital Pharmacy
17.4.2. Retail Pharmacy
17.4.3. Online Pharmacy
17.5. Market Value Forecast By Country, 2015-2025
17.5.1. GCC Countries
17.5.2. South Africa
17.5.3. Israel
17.5.4. Rest of Middle East & Africa
17.6. Market Attractiveness Analysis
17.6.1. By Drug Class
17.6.2. By Route of Administration
17.6.3. By Distribution Channel
17.6.4. By Country
18. Competition Landscape
18.1. Market Player – Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2016)
18.3. Company Profiles
18.3.1. Basilea Pharmaceutica Ltd.
18.3.1.1. Overview
18.3.1.2. Financials
18.3.1.3. Recent Developments
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. The Medicines Company
18.3.2.1. Overview
18.3.2.2. Financials
18.3.2.3. Recent Developments
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Theravance Biopharma
18.3.3.1. Overview
18.3.3.2. Financials
18.3.3.3. Recent Developments
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Allergan
18.3.4.1. Overview
18.3.4.2. Financials
18.3.4.3. Recent Developments
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Merck & Co., Inc.
18.3.5.1. Overview
18.3.5.2. Financials
18.3.5.3. Recent Developments
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. Pfizer, Inc.
18.3.6.1. Overview
18.3.6.2. Financials
18.3.6.3. Recent Developments
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
List of Tables
Table 01: Global MRSA infection Prevalence (%), 2015
Table 02: Global MRSA infection Prevalence (%), 2015
Table 03: Global MRSA infection Prevalence (%), 2015
Table 04: MRSA Drugs: Pipeline Snapshot, 2016
Table 05: MRSA Drugs: Pipeline Snapshot, 2016
Table 06: MRSA Drugs: Competitive Landscape
Table 07: Global MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 08: Global MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 09: Global MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
Table 10: Global MRSA Drugs Market Size (US$ Mn) Forecast, by Region, 2015-2025
Table 11: North America MRSA Drugs Market Size (US$ Mn) Forecast, by Country, 2015-2025
Table 12: North America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 13: North America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 14: North America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
Table 15: Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
Table 16: Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 17: Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 18: Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
Table 19: Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
Table 20: Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 21: Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 22: Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
Table 23: Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
Table 24: Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 25: Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 26: Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
Table 27: Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
Table 28: Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
Table 29: Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
Table 30: Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
List of Figures
Fig. 01: Global MRSA Drugs Market Size (US$ Mn) and Distribution (%) by Geography, 2017 and 2025
Fig. 02: Global MRSA Drugs Market Value Share, by Drug Class (2016)
Fig. 03: Global MRSA Drugs Market Value Share, by Route of Administration (2016)
Fig. 04: Global MRSA Drugs Market Value Share, by Distribution Channel (2016)
Fig. 05: Global MRSA Drugs Market Value Share, by Region (2016)
Fig. 06: Key Manufacturers: Comparison Analysis
Fig. 07: Global MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 08: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipopeptide, 2015-2025
Fig. 09: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oxazolidinone, 2015-2025
Fig. 10: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cephalosporin, 2015-2025
Fig. 11: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Tetracycline, 2015-2025
Fig. 12: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Folate Antagonist, 2015-2025
Fig. 13: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Drug Classes, 2015-2025
Fig. 14: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipoglycopeptide, 2015-2025
Fig. 15: Global MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 16: Global MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 17: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral Route of Administration, 2015-2025
Fig. 18: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral Route of Administration, 2015-2025
Fig. 19: Global MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 20: Global MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 21: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015-2025
Fig. 22: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015-2025
Fig. 23: Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
Fig. 24: Global MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 25: Global MRSA Drugs Market Value Share, by Region, 2017 and 2025
Fig. 26: Global MRSA Drugs Market Attractiveness, by Region, 2017-2025
Fig. 27: North America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
Fig. 28: North MRSA Drugs Market Attractiveness, by Country, 2017-2025
Fig. 29: North America MRSA Drugs Market Value Share, by Country, 2017 and 2025
Fig. 30: North America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 31: North America MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 32: North America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 33: North America MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 34: North America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 35: North America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 36: Europe MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
Fig. 37: Europe MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
Fig. 38: Europe MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 39: Europe MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 40: Europe MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 41: Europe MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 42: Europe MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 43: Europe MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 44: Europe MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 45: Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
Fig. 46: Asia Pacific MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
Fig. 47: Asia Pacific MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 48: Asia Pacific MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 49: Asia Pacific MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 50: Asia Pacific MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 51: Asia Pacific MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 52: Asia Pacific MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 53: Asia Pacific MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 54: Latin America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
Fig. 55: Latin America MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
Fig. 56: Latin America MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 57: Latin America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 58: Latin America MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 59: Latin America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 60: Latin America MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 61: Latin America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 62: Latin America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 63: Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
Fig. 64: Middle East & Africa MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
Fig. 65: Middle East & Africa MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Fig. 66: Middle East & Africa MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
Fig. 67: Middle East & Africa MRSA Drugs Market Attractiveness, by Drug Class, 2017-2025
Fig. 68: Middle East & Africa MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
Fig. 69: Middle East & Africa MRSA Drugs Market Attractiveness, by Route of Administration, 2017-2025
Fig. 70: Middle East & Africa MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Fig. 71: Middle East & Africa MRSA Drugs Market Attractiveness, by Distribution Channel, 2017-2025
Fig. 72: Global MRSA Drugs Market Share, by Company, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market
